ClinicalTrials.gg
CompletedNCT05631795ALPINISTUpdated Jul 9, 2026Results posted

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

A Phase 4 interventional study of Alpelisib and Fulvestrant in Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in India. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2022, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease had progressed on or after endocrine-based treatment.

Read the detailed description

The study was planned to enroll 40 participants. During the treatment phase, participants were treated with alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and on Day 1 of every cycle thereafter (± 3 days) in a 28-day cycle.

The planned duration of treatment was 6 months. Participants could be discontinued from treatment earlier due to unacceptable toxicity, disease progression, withdrawal of consent, or at the discretion of the investigator or the participant. For participants who were ongoing on treatment at the end of the planned study duration and who, in the opinion of the investigator, were still deriving clinical benefit from alpelisib, every effort was made to continue provision of study treatment via post-trial access (PTA).

02

Conditions studied

  • Advanced Breast Cancer

Keywords

  • HR+
  • HER2-negative
  • PI3K
  • CDK4/6 inhibitor
  • ER+
  • PgR+
  • men
  • postmenopausal
  • aromatase inhibitor
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with confirmed PIK3CA mutant advanced or breast cancer
  • females and males ≥ 18 years old with confirmed HR-positive, -negative advanced or metastatic breast cancer.
  • Adequate liver function
  • Adequate renal function
  • Fasting plasma glucose (FPG) ≤140 mg/dL (7.7 mmol/L) and glycosylated () ≤ 6.4%
  • (Eastern Cooperative Oncology Group) Performance Status \< 2
  • Fasting Serum amylase ≤ 2 × and Fasting Serum lipase ≤ ULN
  • Potassium within normal limits, or corrected with supplements
  • Calcium (corrected for serum albumin) and magnesium within normal limits or ≤ grade 1 if judged clinically not significant by the investigator

Key Exclusion Criteria:

  • Known to alpelisib or fulvestrant, or to any of the of alpelisib or fulvestrant
  • Participant ineligible for endocrine therapy per the investigator's judgment
  • Participant has received prior treatment with any PI3K inhibitors and / or mTOR inhibitor
  • Participant with type I diabetes or not controlled type II (based on FPG and HbA1c, see inclusion criterion 6)
  • Participant has a concurrent or malignancy within 3 years of study screening period, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
  • Participant has not recovered to grade 1 or better from related side effects of prior anti cancer therapy (with the exception of alopecia)
  • Participants receiving concomitant agents or chronic use at the time of study entry except in cases outlined below: Topical applications, inhaled sprays, eye drops or local injections are allowed. Participants on stable low dose of corticosteroids for at least two weeks prior to enrollment are allowed
  • Bilateral diffuse lymphangitic carcinomatosis
  • Participants with a known history of seropositivity. Screening for HIV infection at baseline is not required
  • Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose warfarin and acetylsalicylic acid or equivalent, as long as the is ≤2.0)
  • Any severe and/ or uncontrolled medical conditions
  • Participant with severe liver impairment ( score B/C)
  • Participant has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
  • Participant has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in the clinical study
  • Participant has documented pneumonitis/interstitial lung disease which is active and requiring treatment
  • Participant has active cardiac disease or a history of cardiac dysfunction
  • Participants with unresolved osteonecrosis of the jaw
  • Participant has a history of severe cutaneous reactions like Stevens-Johnson-Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  • Participant is a nursing (lactating) or pregnant woman
  • Participant is a woman of defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during study treatment and at least for 1 week (for alpelisib) or 1 year (for fulvestrant based on prescribing label) after the last dose of each study drug (whichever comes later).
  • Participant is a sexually active male unwilling to use a condom during intercourse while taking study treatment, and for 1 week (for alpelisib) or 1 year (for fulvestrant based on prescribing label) after stopping each study drug (whichever comes later). A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm during study and up to the time period specified above.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Alpelisib + fulvestrant

    Alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28 day cycle.

    Drug: Alpelisib · Drug: Fulvestrant

Interventions

  • Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1

    Also known as: BYL719

  • Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One On-treatment Adverse Events (AEs)

    Treatment-Emergent Adverse Events (TEAEs) were defined as the adverse events that occurred, or worsened, during the treatment period (i.e. from the first dose of treatment up to 30 days after the last dose of study drug).

    Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months

Secondary outcomes

  1. Percentage of Participants With Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital anomaly or birth defect in the offspring of a study participant, or was an abnormal pregnancy outcome.

    Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months

  2. Percentage of Participants With Adverse Drug Reactions (ADRs)

    An Adverse Drug Reaction (ADR) was defined as an adverse event (AE) that, in the investigator's judgment, was causally suspected to be related to the study treatment.

    Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months

07

Results

Posted Jun 25, 2026

Participant flow

This study was conducted at 16 centers in India.

Participant flow — Overall Study
MilestoneAlpelisib + Fulvestrant
Started40
Completed21
Not completed19
Withdrew: Adverse event4
Withdrew: Physician decision1
Withdrew: Death1
Withdrew: Progressive disease7
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryPercentage of Participants With at Least One On-treatment Adverse Events (AEs)

Treatment-Emergent Adverse Events (TEAEs) were defined as the adverse events that occurred, or worsened, during the treatment period (i.e. from the first dose of treatment up to 30 days after the last dose of study drug).

Time frame:
From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One On-treatment Adverse Events (AEs)
Percentage of participantsAlpelisib + Fulvestrant
Percentage of Participants With at Least One On-treatment Adverse Events (AEs)100 (91.2 to 100)
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital anomaly or birth defect in the offspring of a study participant, or was an abnormal pregnancy outcome.

Time frame:
From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participantsAlpelisib + Fulvestrant
Percentage of Participants With Serious Adverse Events (SAEs)25 (12.7 to 41.2)
SecondaryPercentage of Participants With Adverse Drug Reactions (ADRs)

An Adverse Drug Reaction (ADR) was defined as an adverse event (AE) that, in the investigator's judgment, was causally suspected to be related to the study treatment.

Time frame:
From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Drug Reactions (ADRs)
ParticipantsAlpelisib + Fulvestrant
Subjects with at least one TEAE related to Alpelisib39
Subjects with at least one TEAE related to Fulvestrant7

Adverse events

Collected over On-treatment Adverse Events (AEs) and deaths were collected from first dose of study medication until the last dose plus 30 days safety follow-up, assessed up to approximately 7 months.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpelisib + Fulvestrant4/40 (10%)10/40 (25%)40/40 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAlpelisib + Fulvestrant
DiarrhoeaGastrointestinal disorders2/40
StomatitisGastrointestinal disorders2/40
VomitingGastrointestinal disorders2/40
FatigueGeneral disorders and administration site conditions2/40
HyperglycaemiaMetabolism and nutrition disorders2/40
DyspnoeaRespiratory, thoracic and mediastinal disorders2/40
AnaemiaBlood and lymphatic system disorders1/40
Cardio-respiratory arrestCardiac disorders1/40
GastritisGastrointestinal disorders1/40
NauseaGastrointestinal disorders1/40
Most frequent other events
Showing 10 of 81
Most frequent other events
EventAlpelisib + Fulvestrant
HyperglycaemiaMetabolism and nutrition disorders36/40
StomatitisGastrointestinal disorders15/40
DiarrhoeaGastrointestinal disorders14/40
VomitingGastrointestinal disorders9/40
Decreased appetiteMetabolism and nutrition disorders8/40
NauseaGastrointestinal disorders7/40
FatigueGeneral disorders and administration site conditions5/40
PyrexiaGeneral disorders and administration site conditions5/40
Weight decreasedInvestigations5/40
AstheniaGeneral disorders and administration site conditions4/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alpelisib + Fulvestrant
Mean54.9 ± 9.71
Sex: Female, Male
Sex: Female, Male(Participants)Alpelisib + Fulvestrant
Female40
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpelisib + Fulvestrant
American Indian or Alaska Native0
Asian40
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

12 sites
  • Novartis Investigative Site
    Guwahati, Assam 781016, India
  • Novartis Investigative Site
    Surat, Gujarat 395009, India
  • Novartis Investigative Site
    Thalassery, Kerala 670103, India
  • Novartis Investigative Site
    Trivandrum, Kerala 695 011, India
  • Novartis Investigative Site
    Bhopal, Madhya Pradesh 462001, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400 012, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 440001, India
  • Novartis Investigative Site
    Pune, Maharashtra 411040, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500004, India
  • Novartis Investigative Site
    Ahmedabad, 380016, India
  • Novartis Investigative Site
    Kolkata, 700026, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Jun 2025, 34 months.

Results were first posted in Jun 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Nov 30, 2022
StartActual
Aug 9, 2022
Primary completionActual
Jun 12, 2025
CompletionActual
Jun 12, 2025
Results first posted
Jun 25, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05631795
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Aug 9, 2022
Primary completion
Jun 12, 2025
Completion
Jun 12, 2025
Results posted
Jun 25, 2026
Last update
Jul 9, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion